Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in Type 1 Autoimmune Pancreatitis
NCT07862075Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 4 trial of inebilizumab in autoimmune pancreatitis type 1, sponsored by Ruijin Hospital. Started Oct 2025; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
autoimmune pancreatitis type 1
Beyond the preview
Go deeper on NCT07862075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862075.